UBS Group’s Sarepta Therapeutics SRPT Stock Holding History

UBS Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,000	Closed	-$323K	–	11134
2025 Q4	$323K	Buy	+15,000	New	+$316K	﹤0.01%	6318
2024 Q3	–	Sell	-12,000	Closed	-$1.9M	–	10035
2024 Q2	$1.9M	Buy	+12,000	New	+$1.54M	﹤0.01%	3821
2023 Q4	–	Sell	-9,400	Closed	-$1.14M	–	9852
2023 Q3	$1.14M	Buy	+9,400	New	+$1.06M	﹤0.01%	3954
2019 Q4	–	Sell	-10,000	Closed	-$753K	–	8385
2019 Q3	$753K	Buy	+10,000	New	+$1.18M	﹤0.01%	4219
2017 Q1	–	Sell	-50,000	Closed	-$1.37M	–	7942
2016 Q4	$1.37M	Sell	50,000 -4,400	-8%	-$177K	﹤0.01%	3275
2016 Q3	$3.34M	Sell	54,400 -195,600	-78%	-$5.91M	﹤0.01%	2400
2016 Q2	$4.77M	Buy	+250,000	New	+$4.63M	﹤0.01%	1983
2015 Q1	–	Sell	-8,800	Closed	-$127K	–	9342
2014 Q4	$127K	Buy	+8,800	New	+$149K	﹤0.01%	5463

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's SRPT Position: Q1 2026 in Review

UBS Group increased its Sarepta Therapeutics (SRPT) stake by 8.4% in Q1 2026, buying an estimated $3.36M and bringing the position to 2,232,459 shares worth $48.6M. The position accounts for 0.01% of the portfolio, ranked #1673.

UBS Group first reported a position in SRPT in Q4 2014 and has held it in 46 quarters since. The position peaked at $180M in Q4 2024. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

UBS Group held 2,232,459 shares of Sarepta Therapeutics worth $48.6M as of Q1 2026.
UBS Group bought 173,758 Sarepta Therapeutics shares in Q1 2026, an estimated $3.36M.
Sarepta Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1673 holding.
UBS Group first reported a position in Sarepta Therapeutics in Q4 2014 and has held it in 46 quarters since.
UBS Group's Sarepta Therapeutics position peaked at $180M in Q4 2024.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.